Concurrent Use of Sublocade and Suboxone – Evidence‑Based Recommendations

Indications and Contraindications

Routine concurrent administration of the monthly buprenorphine depot (Sublocade) and the daily sublingual buprenorphine/naloxone product (Suboxone) is not recommended for maintenance therapy in patients with opioid use disorder because the two agents occupy the same mu‑opioid receptors without added benefit and increase the risk of excessive sedation and respiratory depression. [@1]
The only clinical situation in which brief overlap of both products may be appropriate is during the initial transition from Suboxone to Sublocade; after the transition, Suboxone should be discontinued. [@1]

Sublocade is administered as a subcutaneous depot injection once every 28–30 days; it provides continuous buprenorphine release that maintains steady therapeutic plasma concentrations throughout the month. [@1]
Suboxone is taken sublingually (tablet or film) on a daily basis; peak buprenorphine plasma levels occur 1–3 hours after dosing, with a shorter duration of action compared with the depot formulation. [@2]

Weeks 1–2: Continue the patient’s established daily Suboxone dose (≈16 mg daily) while the first Sublocade injection is administered, allowing the depot to begin releasing buprenorphine. [@1]
Weeks 3–4: Gradually taper Suboxone (reduce the daily dose by roughly 25–50 % each week) as Sublocade approaches steady‑state plasma levels, which typically occur 7–14 days after injection. [@1]
After Week 4: Discontinue Suboxone entirely once Sublocade provides full coverage, eliminating medication redundancy. [@1]

QT‑prolonging medications should be screened for and avoided before initiating or combining any buprenorphine formulation, because concurrent use can precipitate cardiac arrhythmias. [@1]
Respiratory depression risk rises when two buprenorphine sources are combined, especially in patients who also use benzodiazepines or other central‑nervous‑system depressants; the FDA issues a black‑box warning for this combination. [@3]
Take‑home naloxone kits and overdose‑prevention counseling should be provided at every visit for patients receiving any buprenorphine therapy, given the elevated overdose risk if relapse to illicit opioids occurs. [@3]
Comprehensive care includes routine screening for hepatitis C and HIV infection as part of standard addiction‑treatment protocols. [@3]

All facts are presented in English, with patient‑specific details replaced by generic descriptors.